Displaying 593 (all) recruiting clinical trials.
-
Serologic Testing and Genomic Analysis of Autoimmune Immune-Mediated and Rheumatic Patients with COVID-19 (SAGA)
This is a prospective cohort study involving all subjects enrolled in the Web-based Assessment of Autoimmune, Immune-Mediated, and Rheumatic Patients during the COVID-19 Pandemic (WARCOV ...Phase N/A
Non-Interventional
-
Impact of Weight Loss in Patients with Hypertrophic Cardiomyopathy
This is an observational imaging study to evaluate the cardiac effects of weight loss in obese patients with a BMI >=30 with a confirmed diagnosis ...Phase N/A Non-Interventional
-
Gut microbiome alterations as a mechanism of immune dysregulation in new-onset refractory status epilepticus (NORSE)
We will perform a prospective, observational cohort study, with biospecimen collection, of NORSE subjects and subjects with status epilepticus of known cause (e.g. epilepsy ...Phase N/A Non-Interventional
-
Site for A 78-week trial comparing the effect and safety of once weekly insulin icodec and once daily insulin glargine 100 units/mL both in combination with non-insulin anti-diabetic treatment in insulin na ve subjects with type 2 diabetes
Site for To demonstrate the effect on glycaemic control of once weekly insulin 287, with or without non-insulin anti-diabetic drugs, in insulin naïve subjects with ...Phase
Interventional
-
Gut Microbiome in Food Protein-Induced Enterocolitis Syndrome: An Observational Study
Food protein-induced enterocolitis syndrome (FPIES) is a non IgE-mediated food allergy that manifests with predominantly gastrointestinal symptoms and usually starts in the first year of ...Phase N/A Non-Interventional
-
NEW YORK OSTEOARTHRITIS HAND COHORT
This is an observational, longitudinal registry of patients with hand osteoarthritis (HOA) that broadly aims to assess the clinical spectrum, risk factors, and identify possible ...Phase N/A Non-Interventional
-
A Phase 1b Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
Nivolumab will be investigated at the Food and Drug Administration (FDA)-approved dose of 480 mg intravenous (IV) every 4 weeks until unacceptable toxicity, disease ...Phase
Interventional
-
A Randomized controlled study of a health literacy-informed technology-based approach to support safe medication use by parents after discharge of infants from the neonatal intensive care unit
This is a randomized controlled study of parents of children to be discharged from the neonatal intensive care unit at Bellevue and Elmhurst hospitals. A ...Phase N/A Interventional
-
AALL1732 A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494 NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk Adapted Post-Induction Therapy for High-Risk B-ALL Mixed Phenotype Acute Leukemia and Disseminated B-LLy
The purpose of the study is to determine the safety and efficiency of the investigational medicine Inotuzumab Ozogamicin for patients who have NCI high risk ...
Phase
Interventional
-
AALL1732: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494 NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL Mixed Phenotype Acute Leukemia and Disseminated B-LLy
This is a Children's Oncology Group (COG) phase 3 trial for children (ages 1-25 years) newly diagnosed with high risk B-lymphoblastic leukemia (HR B-ALL ...Phase
Interventional
